Immunology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico.
School of Medicine, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Lupus. 2022 Nov;31(13):1660-1665. doi: 10.1177/09612033221122978. Epub 2022 Aug 30.
Interferon-γ inducible protein-10 (IP-10) is a promising biomarker in systemic lupus erythematosus (SLE). The optimal quantification platform has not yet been identified. We compared the performance of bead-based multiplex assay (Luminex) and high-sensitivity enzyme-linked immunosorbent assay (hs-ELISA) for profiling serum IP-10 as a biomarker of lupus activity.
A cross-sectional study was conducted on outpatients with SLE. Serum IP-10 was measured simultaneously on Luminex and hs-ELISA, and correlation between platforms was assessed. Additionally, IP-10 levels were tested against disease activity and organ involvement.
One-hundred and forty-one patients (88% women; 38 years old) were studied. Median IP-10 levels were 100.9 (125.2) pg/mL by Luminex and 156.5 (191.7) pg/mL by hs-ELISA. Correlation analysis showed Spearman's ρ = 0.621 ( < 0.0001) between Luminex and hs-ELISA. Quantification of IP-10 by Luminex showed a significant correlation (ρ = 0.198; = 0.021) with disease activity, while this was not observed (ρ = 0.036; = 0.683) when measured using hs-ELISA. Serum IP-10 levels were lower in quiescent patients than in those with active disease (70.8 [68.4] versus 114.3 [123.9] pg/mL; = 0.024), with an -ROC = 0.62 ( = 0.029), sensitivity = 47.9%, specificity = 77.5%, and positive likelihood ratio = 2.1. Patients with active arthritis had higher IP-10 levels than non-arthritis patients (158.1 [505.4] versus 94.1 [114.0] pg/mL; = 0.008), with an -ROC = 0.73 ( = 0.0009), sensitivity = 72.7%, specificity = 66.4%, and positive likelihood ratio = 2.1. No other type of organ involvement was identified by serum IP-10.
Luminex performs better than hs-ELISA as a quantification platform for IP-10 as it correlates with disease activity and identifies active arthritis in SLE.
干扰素-γ诱导蛋白-10（IP-10）是系统性红斑狼疮（SLE）有前途的生物标志物。尚未确定最佳的定量平台。我们比较了基于珠子的多重分析（Luminex）和高灵敏度酶联免疫吸附测定（hs-ELISA）在分析血清 IP-10 作为狼疮活动生物标志物方面的性能。
对 SLE 门诊患者进行了一项横断面研究。同时在 Luminex 和 hs-ELISA 上测量血清 IP-10，并评估平台之间的相关性。此外，还测试了 IP-10 水平与疾病活动和器官受累的关系。
研究了 141 名患者（88%为女性；38 岁）。Luminex 检测到的 IP-10 中位数为 100.9（125.2）pg/mL，hs-ELISA 检测到的 IP-10 中位数为 156.5（191.7）pg/mL。相关性分析显示，Luminex 和 hs-ELISA 之间的 Spearman ρ=0.621（<0.0001）。Luminex 定量 IP-10 与疾病活动呈显著相关性（ρ=0.198；=0.021），而 hs-ELISA 则未观察到相关性（ρ=0.036；=0.683）。与活动性疾病患者相比，处于静止状态的患者的血清 IP-10 水平较低（70.8 [68.4] 与 114.3 [123.9] pg/mL；=0.024），ROC 为 0.62（=0.029），灵敏度为 47.9%，特异性为 77.5%，阳性似然比为 2.1。活动性关节炎患者的 IP-10 水平高于非关节炎患者（158.1 [505.4] 与 94.1 [114.0] pg/mL；=0.008），ROC 为 0.73（=0.0009），灵敏度为 72.7%，特异性为 66.4%，阳性似然比为 2.1。未通过血清 IP-10 识别其他类型的器官受累。
Luminex 作为 IP-10 的定量平台比 hs-ELISA 表现更好，因为它与疾病活动相关，并可识别 SLE 中的活动性关节炎。
